No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant for Hepatocellular Carcinoma

2021 ◽  
Author(s):  
Kali Zhou ◽  
Courtney L. Hanlon ◽  
Selena Zhou ◽  
Jennifer L. Dodge ◽  
Yong K. Kwon ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
Portosystemic Shunts

Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients with Hepatitis C

2010 ◽  
Vol 43 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Ivan Zendejas-Ruiz ◽  
Alan W. Hemming ◽  
Chaoru Chen ◽  
Jason J. Schwartz ◽  
John B. Sorensen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Recurrent Hepatocellular Carcinoma ◽  
Liver Transplant Recipients

The interplay between gut microbiota and the immune system in liver transplant recipients and its role in infections

2021 ◽  
Author(s):  
Giuseppe Ancona ◽  
Laura Alagna ◽  
Andrea Lombardi ◽  
Emanuele Palomba ◽  
Valeria Castelli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune System ◽  
Liver Disease ◽  
Gut Microbiota ◽  
Liver Transplant ◽  
Bacterial Infections ◽  
Multidrug Resistant ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

Liver transplantation (LT) is a life-saving strategy for patients with end-stage liver disease, hepatocellular carcinoma and acute liver failure. LT success can be hampered by several short-term and long-term complications. Among them, bacterial infections, especially due to multidrug-resistant germs, are particularly frequent with a prevalence between 19 and 33% in the first 100 days after transplantation. In the last decades, a number of studies have highlighted how gut microbiota (GM) is involved in several essential functions to ensure the intestinal homeostasis, becoming one of the most important virtual metabolic organs. GM works through different axes with other organs, and the gut-liver axis is among the most relevant and investigated ones. Any alteration or disruption of GM is defined as dysbiosis. Peculiar phenotypes of GM dysbiosis have been associated to several liver conditions and complications, such as chronic hepatitis, fatty liver disease, cirrhosis and hepatocellular carcinoma. Moreover, there is growing evidence of the crucial role of GM in shaping the immune response, both locally and systemically, against pathogens. This paves the way to the manipulation of GM as a therapeutic instrument to modulate the infectious risk and outcome. In this minireview we provide an overview of the current understanding on the interplay between gut microbiota and the immune system in liver transplant recipients and the role of the former in infections.

scholarly journals Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A‐VENA Criteria

2019 ◽  
Vol 25 (2) ◽  
pp. 207-216 ◽  
Author(s):  
Courtney B. Sherman ◽  
Spencer Behr ◽  
Jennifer L. Dodge ◽  
John P. Roberts ◽  
Francis Y. Yao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Liver Transplant ◽  
Portal Vein Thrombus ◽  
Transplant Candidates
Sign in / Sign up

Export Citation Format

Share Document